Upstream Bio will report Phase 2 results for verekitug in severe asthma on February 11, 2026.
Quiver AI Summary
Upstream Bio, Inc. has announced that it will release the top-line results of the Phase 2 VALIANT trial for its treatment candidate verekitug on February 11, 2026, at 8:00 a.m. ET. Verekitug is notable as the only antagonist in clinical development that targets the thymic stromal lymphopoietin (TSLP) receptor, aimed at treating severe asthma. The VALIANT trial involved 478 patients and examined the safety and efficacy of verekitug over up to 60 weeks with various dosing regimens. The company invites interested parties to access a live webcast of the results on its website. Upstream Bio is focused on developing treatments for inflammatory diseases, particularly severe respiratory disorders, in response to unmet medical needs.
Potential Positives
- Upstream Bio is set to report top-line results from the Phase 2 VALIANT trial of verekitug, a significant milestone in their clinical development process for treating severe asthma.
- Verekitug is the only known antagonist in clinical development targeting the TSLP receptor, highlighting its potential uniqueness and relevance in addressing inflammatory diseases.
- The VALIANT trial involves a large patient population of 478 participants, which adds robustness to the study outcomes and the company's credibility in clinical research.
Potential Negatives
- The upcoming report on the Phase 2 VALIANT trial results on February 11, 2026, implies that the company has not yet demonstrated the efficacy or safety of verekitug, which could impact investor confidence and market perception.
- The reliance on a single drug, verekitug, for addressing multiple severe conditions may raise concerns about the company's portfolio diversification and long-term sustainability if the drug does not perform well in trials.
- There is no mention of previous trial results or data, which could indicate a lack of transparency regarding past performance and may lead to skepticism among stakeholders.
FAQ
When will Upstream Bio report VALIANT trial results?
Upstream Bio will report top-line results from the Phase 2 VALIANT trial on February 11, 2026, at 8:00 a.m. ET.
What is the VALIANT trial focused on?
The VALIANT trial evaluates the safety and efficacy of verekitug for treating severe asthma.
How many patients were involved in the VALIANT trial?
The VALIANT trial included 478 patients with severe asthma.
What is verekitug?
Verekitug is an antagonist targeting the thymic stromal lymphopoietin (TSLP) receptor, currently in clinical development.
Where can I access the webcast for trial results?
The webcast can be accessed via Upstream Bio's website in the Events section on February 11, 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$UPB Hedge Fund Activity
We have seen 72 institutional investors add shares of $UPB stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALTSHULER SHAHAM LTD removed 1,977,619 shares (-58.3%) from their portfolio in Q3 2025, for an estimated $37,199,013
- NORGES BANK added 1,912,731 shares (+197.2%) to their portfolio in Q4 2025, for an estimated $51,930,646
- UBS GROUP AG added 1,533,972 shares (+563.4%) to their portfolio in Q4 2025, for an estimated $41,647,339
- DEEP TRACK CAPITAL, LP removed 1,442,767 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $27,138,447
- VR ADVISER, LLC removed 1,126,021 shares (-49.1%) from their portfolio in Q3 2025, for an estimated $21,180,455
- PICTET ASSET MANAGEMENT HOLDING SA added 773,148 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,990,968
- TCG CROSSOVER MANAGEMENT, LLC removed 684,660 shares (-24.4%) from their portfolio in Q3 2025, for an estimated $12,878,454
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$UPB Analyst Ratings
Wall Street analysts have issued reports on $UPB in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 12/18/2025
- Evercore ISI Group issued a "Outperform" rating on 11/18/2025
- Truist Securities issued a "Buy" rating on 10/14/2025
To track analyst ratings and price targets for $UPB, check out Quiver Quantitative's $UPB forecast page.
$UPB Price Targets
Multiple analysts have issued price targets for $UPB recently. We have seen 4 analysts offer price targets for $UPB in the last 6 months, with a median target of $45.0.
Here are some recent targets:
- Joseph Catanzaro from Mizuho set a target price of $51.0 on 12/18/2025
- An analyst from LifeSci Capital set a target price of $43.0 on 12/02/2025
- Cory Kasimov from Evercore ISI Group set a target price of $40.0 on 11/18/2025
- Danielle Brill from Truist Securities set a target price of $47.0 on 10/14/2025
Full Release
WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET.
The VALIANT trial (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug for up to 60 weeks, with a minimum of 24 weeks of treatment, in 478 patients with severe asthma. Participants were randomized into one of four groups, receiving either 100 mg of verekitug every 24 weeks, 400 mg of verekitug every 24 weeks, 100 mg of verekitug every 12 weeks, or placebo, administered subcutaneously.
Webcast Information
Upstream Bio’s webcast to discuss the top-line results from the Phase 2 VALIANT trial will begin Wednesday, February 11, 2026, at 8:00 a.m. ET. The live webcast can be accessed via this
link
or on the Events tab on the Investors section of the Company’s website at
https://investors.upstreambio.com/news-events/events
. A replay of the webcast will be available on the website following the call.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit
www.upstreambio.com
.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
[email protected]
